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http:WHAT THIS PAPER ADDS
Perilesional skin from patients with critical limb ischemia represents a valid in vivo model of prolonged ischemic
injury for the study of hepatocyte growth factor (HGF) and the c-Met pathway, as well as hypoxia inducible
factor-1. These molecules have been studied mainly on tumor models in the past. In this in vivo model, for the
ﬁrst time not only has the total c-Met receptor, but also its phosphorylated (i.e. activated) form been studied.
Interestingly, no abnormalities in the total c-Met receptor were observed, while a lack of Met phosphorylation
was found, together with a reduced circulating HGF.Objectives: Hepatocyte growth factor (HGF), the c-Met receptor, and hypoxia-inducible factor (HIF) are crucial for
regenerative processes including ischemic wound healing. The aims of the present study are (a) to analyze the
tissue c-Met and HIF-1a expression in skin from patients with critical limb ischemia (CLI); (b) to compare the
serum HGF levels of CLI and control subjects.
Methods: This is a prospective, controlled, single-center study. Thirty-seven patients were enrolled. A skin sample
adjacent to the ischemic lesion was taken from 20 patients with CLI; skin samples were taken from the surgical
wounds of 17 patients surgically treated for abdominal aortic aneurysm as healthy controls. Serum samples were
taken in all cases. Samples were formalin ﬁxed, parafﬁn embedded, and routinely processed. Tissue inﬂammation
was histologically assessed. Immunohistochemistry was performed with antibodies against total c-Met receptor,
activated Met (p-Met), and HIF-1a. RT-polymerase chain reaction was used to quantify HIF-1a mRNA. The
enzyme-linked immunosorbent assay was performed to evaluate serum HGF levels.
Results: With immunohistochemistry, while total c-Met was unchanged, different patterns of p-Met positivity
were observed between CLI and control cases (p < .001). In particular, CLI skin showed a total negativity or
membrane positivity for p-Met (19/20 cases), while control skin mainly showed cytoplasmic positivity in the
epidermal basal layer (16/17 cases). HIF-1a was diffusely lost in CLI, but HIF-1a mRNA was threefold higher than
in controls. Finally, mean serum HGF levels were 590.5 pg/mL and 2380.0 pg/mL in CLI and control groups
respectively (p < .001).
Conclusions: In CLI patients a signiﬁcant decrease in serum HGF levels, concomitant with a loss of skin HIF-1a
stabilization and a lack of c-Met phosphorylation were seen, probably driving a decrease in wound-healing
functions. The next hypothesis is that HGF application might reactivate the c-Met receptor, stabilizing the normal
wound healing process.
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Patients with critical limb ischemia (CLI) not eligible for
revascularization are frequently treated by major amputa-
tion.1,2 Recently innovative treatments for CLI have been
investigated, such as regenerative therapy which includes
the use of stem cells and growth factors, with very
encouraging results regarding foot salvage and wound
healing in patients not eligible for revascularization.3e5
Hepatocyte growth factor (HGF) is a 84-kDa dimeric
molecule described as a fundamental growth factor for liver
regeneration.6,7 Decades ago the product of the c-Met pro-
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types, was identiﬁed as the receptor of HGF.8 c-Met is
composed of an extracellular a-subunit, which binds HGF, as
well as a transmembrane b-subunit with tyrosineekinase
activity: the HGF leads to phosphorylation of the tyrosine
residues of the Met receptor, which become activated
(phosphorylated Met, p-Met).7,9 In the last few years, the
HGF/Met pathway has been described as playing a key role in
human tissues, including the promotion of cell growth, tissue
homeostasis, and neoangiogenesis, concomitantly with anti-
inﬂammatory and anti-ﬁbrogenic activities10e12 (Fig. 1). The
activation of neoangiogenesis and the promotion of cell
survival by the HGF/Met pathway has also been described in
the wound repair processes of the skin, though most studies
in the literature have been conducted on cell cultures or ro-
dent models,13e15 and the few studies on human skin tissue
were focused on primary skin neoplasms.16,17
Hypoxia inducible factor-1 (HIF-1) is composed of two
subunits (a and b). During hypoxia the degradation of the
HIF-1a subunit is abolished, the a and b subunits dimerize
to form a stable HIF-1 molecule, which drives the expression
of growth factors, including the gene encoding for the Met
receptor itself.18,19 Thus, HIF-1 is not directly linked to theFigure 1. HGF/c-met receptor pathway and HIF1a biological functions
leads to tyrosine phosphorylation. The activation of the c-met recepto
Grb-2eSOS complex activates the RAS cascade and Gab-1, connected to
migration or cell homeostasis. HIF1alfa protein activates transcription
factor protein which promote cell growth, neoangiogenesis and wounHGF/Met pathway, but it is able to regulate it, by inﬂu-
encing the amount of the Met receptor on the cell surface
(Fig. 1). HIF-1a stabilization has been shown to play a
pivotal role in skin wound repair in the mouse model.20
Once more, in vivo studies on the human skin model are
lacking in the literature.
The aims of the present study are (a) to analyze the tissue
activation of the Met cellular receptor, additionally to the
HIF-1a expression in skin samples of patients with CLI,
which represent a reliable model of chronic ischemic stress
in vivo; (b) to compare the serum HGF levels from CLI pa-
tients and control subjects.
MATERIALS AND METHODS
The present study is a prospective, controlled, single-center
study.Patients and tissue sampling
From February 2012 to September 2012 a study group was
prospectively enrolled including patients with peripheral
arterial occlusive disease (PAOD) who were Rutherford
categories 5e6 and candidates for surgical or endovascular. The binding of HGF protein to c-Met receptor at the cell surface
r recruits downstream adaptor molecules. The recruitment of the
different signaling protein, leads to proliferation, angiogenesis, cell
of vascular endothelial growth factor and platelet-derived growth
d repair.
432 F. Vasuri et al.revascularization, and a control group of patients with
abdominal infrarenal aortic aneurysm (AAA) candidate for
endovascular or “open” repair. Exclusion criteria were any
concomitant liver disease21 for both groups, and the
occurrence of renal pathologies22 and peripheral arterial
obstructive disease (patients were studied by a duplex scan)
for the control group. All patients from both groups
received anti-platelet therapy as unique treatment. No local
or systemic vasodilators or other medications with
demonstrated effect on tissue perfusion were used.
From each CLI patient a macroscopically not-necrotic skin
sample was taken from within 1 cm of the borders of the
trophic lesion. This procedure was performed during minor
amputation or within 30 min of the end of revasculariza-
tion. From the control group a healthy skin sample was
taken from the surgical access. All skin samples were
promptly ﬁxed in formalin and submitted to the Pathology
Unit. Blood samples were obtained from all patients at least
1 h prior to treatment. Nine healthy subjects were recruited
as negative controls to assess the basic levels of serum HGF
in subjects without chronic ischemia.
Ethical aspects
All patients gave informed consent for skin and blood
sampling prior to treatment. This study conformed to the
ethical guidelines of the 1975 Declaration of Helsinki (and
following modiﬁcations).
Histology and immunohistochemistry
Skin samples were sampled, routinely processed, and
parafﬁn embedded. From parafﬁn blocks 3-mm-thick sec-
tions were cut for hematoxylineeosin stain and immuno-
histochemistry (IHC). Tissue inﬂammation was histologically
described and semi-quantiﬁed as absent, mild/focal, mod-
erate, and severe/diffuse. IHC was performed manually:
sections were rehydrated with graded steps in ethanol.
Antigen retrieval was performed as described in Table 1,
and endogenous peroxidase activity was blocked with H2O2
3% in absolute methanol for 10 min at room temperature.
Antibodyeantigen reaction was obtained by means of
NovoLink Polymer Detection Kit (Novocastra, Newcastle,
UK). Sections were therefore incubated for 1 h at room
temperature in a moist chamber at 4 C with the primary
antibodies, then together with NovoLink Polymer for 30 min
at room temperature and with DAB (NovoLink DAB Sub-
strate Buffer) for 30 s to 2 min. Nuclei were counterstained
with Mayer’s hematoxylin (Sigma Chemicals, Gillingham,
UK). Negative controls were obtained by omitting theTable 1. Technical characteristics of the antibodies used for immunoh
Name Clone Dilution Antigen retrieval
c-Met C-12 1:100 Citrate buffer (pH 6),
heat mediated
p-Met Tyr 1234 1:50 EDTA 1 mmol (pH 8)
heat mediated
HIF-1a ESEE122 1:5500 TriseEDTA 50 mmol-
(pH 9), heat mediateprimary antibodies. Endothelial cells of dermal and hypo-
dermic arterial vessels were used as positive controls for c-
Met, p-Met, and HIF-1a.
RT-PCR analysis
The reverse transcription assay was performed following
the manufacturer’s protocol (High capacity cDNA Archive
kit, Applied Biosystem). RT-polymerase chain reaction (PCR)
was carried out following MasterMix TaqMan Protocol
(TaqMan Univ PCR MasterMix, Applied Biosystems). Four
microliters of neat cDNA were ampliﬁed using speciﬁc
probes for HIF-1a (NC_000014.8) and GUSB (Applied Bio-
systems) in the real-time PCR mix (TaqMan Gene Expression
Assay, Applied Biosystems, respective ID assay: Hs
00936368_m1 and Hs04187831_g1). Reactions were run on
ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems). Cycling conditions were as follows: 2 min at
50 C, 10 min at 95 C, 45 cycles at 95 C for 15 s, and 60 C
for 60 s. Each assay was carried out in triplicate and the
transcription levels were normalized using GUSB as a
reference gene. The expression values for CLI tissues were
presented as fold expression in relation to healthy tissues;
the actual values were calculated using the 2  DDCT
equation, where DDCT ¼ [CT Target  CT GUSB] (CLI
sample)  [CT Target  CT GUSB] (healthy sample).
ELISA assay for serum HGF quantitation
Blood samples were collected in a clot activator tube
(Vacuette, z-serum beads clot activator). Samples were
placed at room temperature for 30 min to allow clotting
and centrifuged at 1800 g for 10 min. The serum obtained
was aliquoted and stored at 80 C until analysis. HGF
serum levels were quantiﬁed with an HGF Human ELISA kit
(Cat#KA043, Abnova Corporation, Taipei, Taiwan). The kit is
a colorimetric solid-phase enzyme-linked immunosorbent
assay (ELISA). The literature was reviewed to estimate the
concentration of the target protein in the sample and a
proper dilution factor was selected so that the diluted
target protein concentration fell near the middle of the
linear regime in the standard curve. According to the
manufacturer’s instructions it was estimated that the HGF
serum concentration level should range from 31.2 to
20,000 pg/mL).
The optical density of each well was determined within
30 min at 450 nm. The standard curve could be plotted as
the relative OD450 of each standard solution (y) versus the
respective concentration of the standard solution (x). The
standard curve was built and GraphPad software generatedistochemistry.
Manufacturer
Santa Cruz Biotechnology, Santa Cruz, CA, USA
, Santa Cruz Biotechnology, Santa Cruz, CA, USA
0.2 mmol
d
Novus Biologicals, Littleton, CO, USA
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concentration of the samples was interpolated from the
standard curve.Statistical analysis
Statistical analysis was performed using SPSS for Windows
(Version 20.0). Continuous variables were expressed as a
means (or medians)  standard deviation (SD) and ranges.
Non-continuous variables were expressed as frequencies.
Analyses of differences between two groups were per-
formed with the ManneWhitney U test and chi square test.
Analyses of differences between more than two groups
were performed with the one-way ANOVA test, followed by
Bonferroni’s adjusted multiple comparison post-test. A p
value < .05 was considered signiﬁcant. RT-PCR data were
analyzed assuming the null hypothesis that the CT differ-
ences between target and reference genes would be the
same in CLI tissue versus AAA tissue. SEM, SD, and the
conﬁdence interval (CI) of 2
ˇ
e(DDCT) were all derived from
the SEM, SD, and CI of DDCT as explained by Yuan et al.23
Statistical tests were performed using SPSS 13.0 for Win-
dows computer software (SPSS, Chicago, IL, USA). To analyze
and represent basic biostatistics, curve ﬁtting, and scientiﬁc
graphing of biological data Prism 5 software (GraphPad
software, Inc) was used.
RESULTS
Patient characteristics
Between February 2012 and September 2012, 37 patients
satisﬁed the inclusion criteria. Twenty patients with CLI in
the study group and 17 patients in the control group were
analyzed, for a total of 29 (78.4%) males and eight (21.6%)
females with a mean age of 72.7  10.1 years (range 36e88
years) (Table 2).
Successful revascularization was achieved in all CLI pa-
tients with no major complications at 30 days. Ten patients
(50%) were treated by femoro-tibial bypass, nine by
femoro-tibial percutaneus transluminal angioplasty (PTA,
45%), and one patient (5%) was treated by a hybrid
approach (bypass and PTA). Thirteen out of 17 (76.5%)
patients in the control AAA group were treated by endo-
vascular aneurysm repair (EVAR), while a conventional openTable 2. Patient demographic features and comorbidity.
All patients Stu
Patients (n) 37 20
Age (mean  SD) 72.28  10.72 75.
Dyslipidemia, n (%) 20 (54.0%) 7 (
Hypertension, n (%) 33 (89.1%) 19
Renal failure, n (%)
Dialysis
No dialysis
12 (32.4%)
3 (8.1%)
9 (24.3%)
12
3 (
9 (
Coronary heart disease, n (%) 22 (59.4%) 14
Cerebrovascular disease, n (%) 5 (13.5%) 5 (
COPD, n (%)
Smokers
20 (54%)
8 (21.6%)
11
2 (
Diabetes mellitus, n (%) 12 (32.4%) 11treatment was performed in the remaining four (23.5%)
patients.
Immunomorphological expression of c-Met and p-Met in
the CLI and control groups
Perilesional skin samples from CLI patients had a variable
degree of ﬂogosis: severe/diffuse in seven (35.0%) cases,
moderate in four (20.0%), and mild or absent in nine
(45.0%). Conversely, ﬂogosis in the 17 control skin samples
was mild or absent in 16 (94.1%) cases, and a moderate
ﬂogosis, of unknown origin, was found in just one (5.9%).
Unsurprisingly, this difference in the amount of ﬂogosis
between the two groups was statistically signiﬁcant
(p ¼ .001, chi-square test).
At IHC, c-Met showed a nuclear and cytoplasmic
expression in the endothelial cells of dermal vessels in all
cases (used as positive controls). In the epidermal epithelial
cells, c-Met was strong and diffuse in 28 of 37 (75.7%)
cases, and weak in 9 (24.3%). c-Met expression in the
epidermis did not change between the two study groups: in
fact it was strong in 14/20 (70.0%) CLI cases and 14/17
(82.4%) control cases (p ¼ .315, chi-square test).
Interestingly, p-Met showed three different patterns of
expression in epidermal epithelial cells: total negativity (14
cases, 37.8%), cytoplasmic positivity localized exclusively in
the basal layer or rarely in all epidermis layers (17 cases,
46.0%), and positivity in cell membranes only (6 cases,
16.2%) (Table 3 and Fig. 2). Unlike c-Met, p-Met expression
varied signiﬁcantly between the two groups: CLI skin
showed a total negativity or membrane-only positivity for p-
Met in 13 (65.0%) and six (30.0%) cases respectively, with
only one (5.0%) case showing cytoplasmic positivity. Control
skin showed cytoplasmic basal layer positivity in 16 (94.1%)
cases and only one (5.9%) totally negative case, with no
cases of membrane positivity. This difference in p-Met
expression between CLI and control groups was statistically
signiﬁcant (p < .001, chi-square test). As expected, the p-
Met pattern correlated with the amount of ﬂogosis as well
(p ¼ .007, data not shown).
Tissue HIF-1a expression
With RT-PCR analysis, mean cycle threshold (CT) values of
endogenous control (GUSB) were 31.67 (SD 1.67, SEM 0.59,dy group Control group p (chi-square)
17
60  10.28 68.79  10.29 0.046
35.0%) 13 (76.4%) 0.015
(95.0%) 14 (82.3%) 0.27
(60.0%)
15.0%)
45.0%)
(Exclusion criteria)
e
(70.0%) 8 (47.0%) 0.150
25%) (Exclusion criteria) e
(55.0%)
10.0%)
9 (52.9%)
6 (35.2%)
0.30
0.254
(55.0%) 1 (6.0%) 0.003
Figure 2. Patterns of p-Met immunostaining in the epidermis: (a)
total p-Met negativity, (b) membrane positivity, and (c) cyto-
plasmic positivity, mainly in the basal layer. Magniﬁcation: 10
(a,b), 20 (c).
Table 3. Distribution of p-Met immunohistochemical positivity
between the two groups of patients. This difference is
statistically signiﬁcant at p < .001 level (chi-square test).
p-Met pattern CLI Control Total
Negative 13 (65.0%) 1 (5.9%) 14 (37.8%)
Membrane only 6 (30.0%) 0 (0.0%) 6 (16.2%)
Cytoplasm basal
layer/epidermis
1 (5.0%) 16 (94.1%) 17 (46.0%)
Total 20 (100.0%) 17 (100.0%) 37 (100.0%)
434 F. Vasuri et al.CI 30.27e33.07) in aortic aneurysm samples and 30.25 (SD
0.14, SEM 0.05, CI 30.13e30.36) in CLI tissue. Mean CT for
tested gene HIF-1a was 31.69 (SD 1.63, SEM 0.58, CI 30.33e
33.06) in control tissue and 28.43 (SD 0.40, SEM 1.14, CI
28.10e28.76) in CLI tissue. DDCT HIF-1a in controls and CLI
tissues were signiﬁcantly different from 0 (p ¼ .028); thus
the null hypothesis was rejected, which indicated a change
in HIF-1a gene expression between controls and CLI tissues.
In CLI tissue, mean DDCT HIF-1a was 1.96 (SD 0.31, SEM
0.16; CI 2.46 to 1.46) and in control tissue DDCT
was 0.13 (SD 0.40, SEM 0.20; CI 0.76 to 0.51). Cor-
responding for CLI to 2
ˇ(DDCT) of 3.891 and 0.917 for
controls. CLI tissue showed a fourfold HIF1-a gene expres-
sion increase compared with the control group (Fig. 3(a)).
With IHC, HIF-1a protein was weak in two (11.8%) of 17
control skin cases compared with 16 (80.0%) of 20 CLI skin
cases (p < .001, chi-square test). Generally, the decrease in
HIF-1a protein in epidermal cells correlated with a positive
expression of the p-Met receptor, indicating activation of
the receptor (p ¼ .005, data not shown). In contrast to
weak expression of HIF-1a protein in CLI patients, HIF1-a
gene expression levels were four times higher than CLI
tissues: these data seem to indicate that a loss in HIF-1a
protein stabilization occurs in CLI skin (Fig. 3(b and c)).
Serum HGF analysis
Mean total serum HGF was 590.5  974.6 pg/mL (range
22.92e6201.51 pg/mL, SD 1752.60). Mean HGF in the
healthy patients pool was 67.40  44.1 pg/mL. Mean HGF
in the CLI patients was 590.5  974.6 pg/mL. Mean HGF in
the AAA control patients was 2698.00  1931 pg/mL
(Fig. 4). Of note, despite the high variability and standard
deviations, HGF serum levels were signiﬁcantly lower in
healthy and CLI patients than in AAA control patients
(p < .001, one-way ANOVA). Bonferroni’s adjusted multiple
comparison test showed that the HGF value between
healthy subjects and CLI patients was not statistically sig-
niﬁcant, while the HGF value between CLI and AAA patients
(p < .001), and between healthy subjects and AAA patient
(p < .001) were signiﬁcant.
DISCUSSION
In patients with CLI and trophic lesions, the treatment of
choice is revascularization associated with debridement
and/or minor amputation. The healing time of trophic le-
sions is often very long, particularly in patients who require
healing by second intention;24,25 therefore, during the lastfew years, different approaches have been experimented
with, aiming to help cell proliferation and angiogenesis,
which represent crucial mechanisms in the wound and ulcer
healing process. One of these approaches could be the local
or systemic use of growth factors after revascularization.
According to this theory, the expression and behavior of the
HGF/c-MET pathway and HIF1a, which seem to play an
Figure 3. (a) At RT-PCR analysis, tissue from critical limb ischemia showed a fourfold increase of expression of the hypoxia inducible factor-
1a (HIF-1a) gene compared with the control group. Conversely, with immunohistochemistry, epidermis of control skin showed an
increased HIF-1a positivity (b) compared to diseased skin (c). Magniﬁcation: 10.
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were assessed in patients with trophic lesions.10e15
In this study a general down-regulation of the HGF/Met
pathway in CLI patients was observed. In particular serum
HGF levels in CLI patients were higher than in the nine
healthy controls, but they were signiﬁcantly lower than the
HGF levels in AAA patients. This indicates repression of HGF
production, at least compared to the other model of chronic
vascular disease (AAA). This means that the HGF/c-MET axis
is inhibited in the ischemic skin of CLI patients and it cannot
accomplish its role of maintaining an adequate process of
cell proliferation and angiogenesis.
In persistent hypoxic and hyperglycemic injuries, HGF is
known to be repressed both in vivo and in vitro by trans-
forming growth factor (TGF)-b and angiotensin, among
others,7,26 and also HIF-1 stability was described to be
decreased in conditions of persistent hyperglycemia and/or
hypoxia.20,27 Considering this, we can easily hypothesize
that the lower serum HGF levels, as well as the lower tissue
positivity for HIF-1a that was found in CLI patients, might be
because CLI ulcers are chronic hypoxic lesions by deﬁnitionFigure 4. Serum levels of hepatocyte growth factor in patients with
critical limb ischemia (CLI) compared to healthy patients and the
control group (abdominal aortic aneurysm [AAA]). CLI patients
showed a signiﬁcantly lower hepatocyte growth factor level
(*p < .001) than AAA patients. The two dots above the CLI column
represent cases out of standard deviation.and that half of the CLI patients in this series were diabetic.
Moreover, fourfold higher levels of HIF-1a mRNA at RT-PCR
were found in diseased CLI skin; although it seems to
contrast with the IHC results, this should not be surprising,
since it is well established in the literature that HIF-1 sta-
bilization and intracellular concentration are regulated
almost invariably at a post-transcriptional level.28 In
ischemic wounds, the loss of HIF-1 stabilization is associated
with increased gene expression, as an attempt by the cell to
preserve HIF-1 concentration and functionality.
Another observation that emerged from these results is
that c-Met IHC positivity in epidermal cells was equivalent
in CLI lesions and healthy skin (p ¼ .315), while Met
phosphorylation changed signiﬁcantly between the two
groups (p < .001). In particular, when almost all control
cases showed a constant positivity in the epidermal basal
layer or in the full thickness of the epidermis, the CLI skin
were completely negative (65% of CLI) or expressed a
distinctive membrane positivity. The general picture seems
to suggest that the amount of c-Met receptor is quite
normally expressed on the cell membrane and that chronic
hypoxia is not able to affect its expression; decreased HIF-1
levels did not affect the expression of the Met gene, surely
because HIF-1 is not the only transcription factor for Met
and this loss in Met phosphorylation is probably attribut-
able to inadequate levels of circulating HGF.
A possible limitation of the present study is represented
by the mean age difference between the study group
(75.60  10.28) and the control group (68.79  10.29). This
difference was signiﬁcant (p ¼ .045, ManneWhitney test)
and quite expected, since two different vascular based pa-
thologies with two different ages of onset were chosen in
this study. Since no inﬂuence of age on circulating HGF and
on the HGF/Met pathway in general has been described in
the literature, it can reasonably be surmised that the
modiﬁcations observed between the two groups are due to
the pathological condition of the CLI patients. Another
possible criticism of this approach could be that patients
with a chronic vascular disease such as AAA cannot be
considered as true control cases. For example, these
436 F. Vasuri et al.patients showed a signiﬁcantly higher incidence of dyslipi-
demia (with a mean body mass index 28.53  2.98 vs.
24.60  4.36 of the CLI patients, p ¼ .022, ManneWhitney
test), which is probably related to aneurysmal disease.
Anyway it is should be kept in mind that patients suffering
from chronic vascular disease are not described as having
inﬂammatory and/or vascular skin changes, unless a trophic
ischemic injury appears. The AAA patient model permitted
obtaining not only serum samples from chronic vasculop-
athy (to be confronted with CLI), but also healthy skin
samples, difﬁcult to obtain otherwise. The absence of a
signiﬁcant ﬂogosis in AAA skin samples supported this
approach. The sample size could represent another limit of
this study, and the lack of a power calculation could imply a
risk of underpowerment. However, this is an explorative
translational study on tissue protein expression, and with
the series numerosity it is acceptable to conclude that there
are evident differences among study groups.
In conclusion, ulcerated skin from CLI patients represent
a valid in vivo model of prolonged ischemic injury: in the
current preliminary data, a general downregulation of the
HGF/Met/HIF axis occurs in this model, with an impairment
in the healing process. The relationship between the
decreasing serum HGF and the lack of activation of tissue
Met receptor cannot be completely clariﬁed here. If this
general downregulation is due to the decreased serum
levels of HGF, it can be assumed that the local or systemic
application of HGF could reactivate the Met receptor, sta-
bilizing the normal wound-healing process. Actually, HGF
has already been used in two clinical trials to treat
PAOD,29,30 but the majority of the treated patients had no
trophic lesions. These results reinforce the rationale of an
application of HGF, at the same time as revascularization, to
reduce the healing time and to enhance limb salvage rates.
Clinical trials and further studies are necessary to conﬁrm a
beneﬁcial role of a combined HGF/revascularization therapy
in patients with CLI.
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